LOXO ONCOLOGY, INC.
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 2013-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.loxooncology.com
A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
- Conditions
- Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
- Interventions
- First Posted Date
- 2021-08-27
- Last Posted Date
- 2025-04-25
- Lead Sponsor
- Loxo Oncology, Inc.
- Target Recruit Count
- 250
- Registration Number
- NCT05023980
- Locations
- 🇨🇳
Hunan Cancer Hospital, Changsha, Hunan, China
🇧🇷Hospital de Clinicas de Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil
🇧🇷Centro Gaucho Integrado - Mae de Deus Center, Porto Alegre, Rio Grande Do Sul, Brazil
A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
- Conditions
- Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
- Interventions
- First Posted Date
- 2021-07-16
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- Loxo Oncology, Inc.
- Target Recruit Count
- 600
- Registration Number
- NCT04965493
- Locations
- 🇮🇹
IRCCS - AOU di Bologna, Bologna, Italy
🇮🇹Ospedale Santa Croce e Carle, Cuneo, Italy
🇮🇹A.O.U. di Modena, Modena, Italy
A Drug Drug Interaction (DDI) Study of Selpercatinib and Dabigatran in Healthy Participants
- First Posted Date
- 2021-03-04
- Last Posted Date
- 2024-05-24
- Lead Sponsor
- Loxo Oncology, Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT04782076
- Locations
- 🇺🇸
Covance Clinical Research Inc, Daytona Beach, Florida, United States
Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
- Conditions
- Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
- Interventions
- First Posted Date
- 2020-12-14
- Last Posted Date
- 2025-04-20
- Lead Sponsor
- Loxo Oncology, Inc.
- Target Recruit Count
- 238
- Registration Number
- NCT04666038
- Locations
- 🇨🇦
Princess Margaret Hospital (Ontario), Toronto, Ontario, Canada
🇺🇸Community Health Network, Indianapolis, Indiana, United States
🇨🇳Southern Medical University Nanfang Hospital, Guangzhou, Guangdong, China
Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)
- Conditions
- Lymphoma, Mantle-Cell
- Interventions
- First Posted Date
- 2020-12-10
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- Loxo Oncology, Inc.
- Target Recruit Count
- 500
- Registration Number
- NCT04662255
- Locations
- 🇺🇸
Alaska Oncology and Hematology, LLC, Anchorage, Alaska, United States
🇺🇸Arizona Oncology Associates, P.C. - HOPE, Phoenix, Arizona, United States
🇺🇸UCLA Medical Center, Los Angeles, California, United States
A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer
- Conditions
- Medullary Thyroid Cancer
- Interventions
- First Posted Date
- 2019-12-26
- Last Posted Date
- 2025-04-20
- Lead Sponsor
- Loxo Oncology, Inc.
- Target Recruit Count
- 291
- Registration Number
- NCT04211337
- Locations
- 🇺🇸
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, California, United States
🇺🇸University of Chicago Medical Center, Chicago, Illinois, United States
🇺🇸The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL
- Conditions
- Waldenstrom MacroglobulinemiaMantle Cell LymphomaSmall Lymphocytic LymphomaChronic Lymphocytic LeukemiaB-cell LymphomaMarginal Zone Lymphoma
- Interventions
- First Posted Date
- 2018-11-14
- Last Posted Date
- 2025-04-06
- Lead Sponsor
- Loxo Oncology, Inc.
- Target Recruit Count
- 860
- Registration Number
- NCT03740529
- Locations
- 🇺🇸
University of Pennsylvania Hospital, Philadelphia, Pennsylvania, United States
🇺🇸Ohio State University Hospital, Columbus, Ohio, United States
🇺🇸Cleveland Clinic Foundation, Cleveland, Ohio, United States